Drug Data Release: Recent buzz on social media has centered around Pyxis Oncology's latest announcement of preliminary Phase 1 data for its cancer drug, Micvotabart Pelidotin, targeting head and neck squamous cell carcinoma. Many users highlighted the impressive efficacy results, noting high response and disease control rates. However, the stock took a sharp hit, with significant premarket declines reported.
Investor Concerns: Despite the positive data, social media discussions reflect worry over the small patient sample size and potential safety issues with the drug. Some have pointed out a longer timeline for further results, expected in 2026, which has fueled uncertainty. A few posts also mentioned a recent financing move, though opinions on its impact remain divided.
Note: This discussion summary was generated from an AI condensation of post data.
Pyxis Oncology Revenue
Pyxis Oncology had revenues of $2.8M in Q2 2025.
You can track PYXS financials on Quiver Quantitative's PYXS stock page.
Pyxis Oncology Hedge Fund Activity
We have seen 26 institutional investors add shares of Pyxis Oncology stock to their portfolio, and 76 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC removed 2,724,529 shares (-77.0%) from their portfolio in Q3 2025, for an estimated $6,048,454
- PERCEPTIVE ADVISORS LLC added 1,178,307 shares (+inf%) to their portfolio in Q3 2025, for an estimated $2,615,841
- ABERDEEN GROUP PLC removed 913,045 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,026,959
- STEMPOINT CAPITAL LP added 689,538 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,530,774
- IKARIAN CAPITAL, LLC removed 613,253 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $674,578
- BANK OF AMERICA CORP /DE/ added 593,853 shares (+2690.9%) to their portfolio in Q3 2025, for an estimated $1,318,353
- LONGAEVA PARTNERS L.P. added 503,214 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,117,135
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Pyxis Oncology Analyst Ratings
Wall Street analysts have issued reports on $PYXS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stephens & Co. issued a "Overweight" rating on 11/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/19/2025
To track analyst ratings and price targets for Pyxis Oncology, check out Quiver Quantitative's $PYXS forecast page.
Pyxis Oncology Price Targets
Multiple analysts have issued price targets for $PYXS recently. We have seen 3 analysts offer price targets for $PYXS in the last 6 months, with a median target of $7.0.
Here are some recent targets:
- Sudan Loganathan from Stephens & Co. set a target price of $8.0 on 11/24/2025
- Brad Canino from Guggenheim set a target price of $7.0 on 11/04/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $5.0 on 08/19/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
